IRWD has executed a masterful partnering strategy that is poised to propel IRWD to profitability in 2013:
Sept 2007 - Forest - covers US, Canada, Mexico
April 2009 - Almirall - covers EU including Russia, Switzerland and Turkey
Nov 2009 - Astellas - covers Japan, S. Korea, Taiwan, Phillipines, Indonesia
Oct 2012 - AstraZeneca - covers China
Analysts see linaclotide as a $1B+ per year drug once commercialization is underway across these regions. Put a typical 4-5X multiple on expected sales and IRWD is grossly undervalued at present.